Immupharma Share Discussion Threads

[badger60] 19/10/2018 08:36

Hemogenyx Pharmaceuticals PLC Collaboration, License and Investment by OrgenesisSource: UK Regulatory (RNS & others)TIDMHEMORNS Number : 5429EHemogenyx Pharmaceuticals PLC19 October 2018Hemogenyx Pharmaceuticals plc("Hemogenyx" or the "Company")Collaboration, License and Investment by Orgenesis for unique mouse modelHemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its wholly owned subsidiary Immugenyx, LLC ("Immugenyx") has entered into a collaboration agreement with Orgenesis, Inc ("Orgenesis"). Orgenesis (NASDAQ: ORGS) is a vertically-integrated biopharmaceutical company with expertise and experience in cell therapy development and manufacturing.Immugenyx will collaborate with Orgenesis on the further development and commercialization of its advanced hematopoietic chimeras (AHC). AHC, a new type of humanised mouse with a functional human immune system, is being developed by Immugenyx as an in vivo platform for disease modelling and the development of drugs and cell therapies.Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented: "As a company committed to the discovery and development of novel therapeutic products for patients suffering from blood and severe autoimmune diseases, we are pleased to partner with Orgenesis, a premier service provider in the regenerative medicine industry and a pioneer in cell reprogramming. The commercial collaboration, license agreement and investment is an additional confirmation of the uniqueness and value of Immugenyx' AHC platform."Vered Caplan, CEO of Orgenesis, commented: "We are excited to collaborate with Immugenyx, as this technology has broad potential to accelerate drug development across a wide range of indications, by mimicking the human immune system within a mouse model. Through this novel platform, our goal is to advance the field of cell therapy through a unique and innovative way of using an in vivo model of the human immune system."According to the terms of the agreement, Orgenesis and/or one or more qualified investors (the "Investors") will advance to Immugenyx a convertible loan in an amount of not less than US$1,000,000 (the "Convertible Loan"). As part of the Agreement, the Investors shall have the right to convert the outstanding Convertible Loan amount into either: (i) shares of Immugenyx at a price per share based on a pre-money valuation of US$8,000,000; or (ii) shares of Orgenesis' common stock at a price per share equal to the weighted average trading price of Orgenesis' common stock for the three trading days preceding conversion.Orgenesis and/or the Investors shall have the option, exercisable at any time up to the third anniversary of the closing of the transaction, to invest additional funds in an amount of up to US$1,000,000 and not less than US$500,000 in Immugenyx.Orgenesis shall have the right to market and serve as a distributor of Immugenyx products. Immugenyx hereby grants Orgenesis and its Affiliates a perpetual (for as long as the current agreement is in force), non-exclusive, worldwide, sublicensable through multiple tiers license to use, market, sell and otherwise commercialize Immugenyx technology, patents and/or products. Immugenyx will retain exclusive rights to manufacture, make and supply to Orgenesis or its Affiliates all Immugenyx technology and/or licensed products that are marketed, sold or otherwise commercialized by Orgenesis or its Affiliates. In consideration for the license, Orgenesis shall pay to Immugenyx a royalty of 12% of Orgenesis' net revenues generated from Immugenyx' technology.Enquiries:

[ken chung] 19/10/2018 08:21

Lemmings and mushrooms only now.

[kop202] 16/10/2018 17:59

Oh the irony. Poster with userid of Bitcoin referring immu investors as gamblers

[nobbygnome] 16/10/2018 09:32

>> Brad

With all due respect I think you and the company are being a little naive. Of course the companies will keep open the dialogue and garner whatever information they can for their own purposes. As we all know Lupus trials are extremely difficult and are evolving all the time so there is always information to be harvested. That is not the same as being genuinely interested in licensing the drug. The fact this wasn't even mentioned in the update shows there is no hope of any deal in the short to medium term IMHO.

[brad44] 16/10/2018 08:44

please contact Lisa at IMM, all companies that signed up to the NDA are still ongoing. MAP extension will be taken at face value. nobody has the right to say that they know what "the regulators" may do or say over the next five minutes, let alone the next 6 months.

[nobbygnome] 16/10/2018 08:39

Just a couple of points.

1. They will spend (waste) the cash.
2. The 'at least 10 Pharmas' were not even mentioned in the last update. I think we can assume not surprisingly they have all exited stage left!
3. The MAP and extension study will not be admissible to regulators because there is no placebo group.

[brad44] 16/10/2018 08:15

au24 he has only "lost" as you put it, if he has sold. I am still confident that Lupuzor has a good chance of getting to market, and the potential for IMM is still there. hope Dallo from LSE doesnt mind me cut and pasting his recent post.

1 MAP ---Now recruiting up to 500 patients
2 Extension Study ---results in Q2 2019
3 Incanthera deal ---hopefully concluded by the end of this year
4 Ureka sale --- timing and proceeds as yet unknown
5 NDAs sent to at least 10 Pharmas
6 Approx £ 9m in cash

The total value of Immupharma is now £ 6m ex cash

It could be bought by a Pharma from it's Staff Canteen Christmas fund jar

Hold tight

[nobbygnome] 15/10/2018 19:55

Interesting to see that reality is finally dawning here; sadly the same does not seem to be happening for the hapless board members.

[au24] 15/10/2018 19:52

A passionate investor a friend of the family has lost 50 grand here. He sold the dream to others l know,who have also lost smaller sums.

[au24] 15/10/2018 19:49

Nothing here to want to hang on to,sadly.

[1retirement] 15/10/2018 17:31

Touched a nerve I see. Don't blame me, blame the........er, umm?!

[badger60] 15/10/2018 07:37

Hemogenyx Pharmaceuticals PLC Collaboration with Johnson & Johnson InnovationSource: UK Regulatory (RNS & others)TIDMHEMORNS Number : 9667DHemogenyx Pharmaceuticals PLC15 October 2018Hemogenyx Pharmaceuticals Plc("Hemogenyx" or the "Company")Immugenyx Enters Collaboration with Johnson & Johnson InnovationHemogenyx Pharmaceuticals Plc (LSE: HEMO; Hemogenyx), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its wholly owned subsidiary, Immugenyx, LLC ("Immugenyx"), has entered into a collaboration agreement with Janssen Research & Development, LLC ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation LLC.Immugenyx will collaborate with Janssen on the development of a model of systemic lupus erythematosus (SLE), the most common form of Lupus, using its advanced hematopoietic chimeras (AHC). AHC, a new type of humanised mouse with a functional human immune system, is being developed by Immugenyx as an in vivo platform for disease modelling and drug development.Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented: "As a company committed to the development of novel therapeutic products for patients suffering from blood and severe autoimmune diseases, we are pleased to partner with Janssen, a world leader in the discovery and development of therapeutics for autoimmune diseases."According to the terms of the agreement, Immugenyx will collaborate with Janssen on research activities that are determined by a mutually approved research plan. Immugenyx shall own the humanised mouse model of Lupus to be developed in collaboration with Janssen. Immugenyx shall grant to Janssen and its Affiliates a perpetual, irrevocable, non-exclusive, fully-paid-up, transferable, worldwide, license to use the Lupus model solely for their own internal research and product development purposes. Financial terms of the collaboration are not disclosed.Enquiries:

[kop202] 12/10/2018 12:41

KenI don't think 1p coins legal tender anymore...could you stretch to 5p?

[borromini1] 12/10/2018 00:38

The size of Dr Robert Zimmer’s (CSO) shareholding effectively blocks any takeover that is not supported by the board. IMM are not going to accept any take over offer or agreement that does not recognise the value of the end scenario of Lupuzor receiving regulatory approval. We can say no Pharma is currently prepared to offer the considerable level of commitment required by the board. Equally no fund raising share issue will occur given the current dilution levels it would generate.

Most may accept that the Managed Access Programme (MAP) is the quickest, most affordable mechanism to achieve greater clarity, one way or another, on whether current Lupuzor works or does not work and for which subsets of Lupus patients. Do we reckon this MAP is the first applied to a Lupus drug? What do the Lupus Foundation of America (LFA) think of this step?

[1retirement] 11/10/2018 17:28

Single digits by next week?

[ken chung] 11/10/2018 08:46

A very high quality short.

[nobbygnome] 11/10/2018 05:50

>> borromini1

Precisely. The fact that no Pharma were prepared to stump up the cash means the chance of success is minimal. So they either have to raise the money themselves to do another phase IIb dose ranging study.....or give up on Lupuzor all together. Although the latter would be a tragedy in many ways, the board's inability to acknowledge the dosing is wrong means that is really the only viable option for shareholders to maintain some value in the company.

Personally I think the management are still in denial....

[borromini1] 10/10/2018 08:49

Hardly a waste of time if Lupus patients start going into remission in significant numbers. One key aim of the MAP is to give investors and bigger pharma, including the current parties under NDA, greater clarity and confidence to invest in funding a second phase 3 or 4 trial.

Meanwhile the Lupus Foundation of America (LFA) and USA Food and Drugs Administration (FDA) are struggling to correct the obfuscation caused by aggressive use of Standard of Care (SoC) drugs in Lupus trials.

IMM have stated a cost for the MAP of £1.1 to £1.2 million. This can be paid from existing cash funds. The option to start a 5 to 6 year development programme for Lupuzor using a different mechanism for a different indication is a terrific idea but where is the money to fund it coming from Nobby?